The A4 Study (Anti-Amyloid Treatment in Asymptomatic Alzheimer's disease) was a landmark Phase 3 secondary prevention trial evaluating solanezumab in cognitively normal older adults with elevated amyloid plaques. This ambitious trial tested the hypothesis that removing amyloid before symptoms appear could prevent or delay the onset of Alzheimer's disease dementia["@study2023"][@secondary2022].
...
Overview
Mermaid diagram (expand to render)
The A4 Study (Anti-Amyloid Treatment in Asymptomatic Alzheimer's disease) was a landmark Phase 3 secondary prevention trial evaluating solanezumab in cognitively normal older adults with elevated amyloid plaques. This ambitious trial tested the hypothesis that removing amyloid before symptoms appear could prevent or delay the onset of Alzheimer's disease dementia["@study2023"][@secondary2022].
The A4 trial represented a paradigm shift in Alzheimer's research, focusing on prevention in individuals with biomarker evidence of preclinical AD rather than treating patients with established dementia. By targeting cognitively normal individuals with amyloid plaques, the study aimed to intervene at the earliest possible stage of the disease process.
Trial Details
| Attribute | Value | |-----------|-------| | NCT Number | NCT02008357 | | Phase | Phase 3 | | Status | Completed (results published) | | Sponsor | Eli Lilly and Company | | Enrollment | 1,169 patients | | Duration | 5 years (240 weeks) | | Study Period | 2013-2023 | | Locations | US, Canada, Japan, Australia, Europe |
Background and Rationale
The Preclinical AD Concept
The A4 trial was based on the understanding that Alzheimer's disease pathology develops decades before clinical symptoms appear:
Amyloid Accumulation: Amyloid plaques begin forming 15-20 years before dementia
Silent Phase: Individuals are cognitively normal despite pathology
Therapeutic Window: Prevention during this phase may be most effective
Secondary Prevention
The A4 study implemented the "secondary prevention" concept:
Target Population: Amyloid-positive but cognitively normal individuals
Goal: Slow or prevent progression to MCI/dementia
Rationale: Treat before irreversible damage occurs
Mechanism of Action
Solanezumab is a humanized monoclonal antibody designed to target amyloid-beta:
Target Specificity
Binds to the central domain of amyloid-beta (amino acids 13-28)
Prefers soluble Aβ monomers and oligomers
Does not bind to dense-core plaques (distinguishing feature)
Therapeutic Approach
Peripheral Sink Effect
Binds Aβ in bloodstream
Creates concentration gradient
Promotes Aβ efflux from brain
Microglial Recruitment
Antibody-opsonized Aβ is phagocytosed
Enhances clearance via immune cells
Synaptic Protection
Prevents soluble Aβ from binding to synapses
May protect against synaptic dysfunction
Trial Design
Study Population
Age: 65-85 years
Cognitive Status: Cognitively normal (MMSE 25-30)
Amyloid Status: Elevated amyloid by PET (Centiloid ≥25)
CDR: Global score 0
Treatment Arms
Solanezumab: 400 mg intravenous every 4 weeks
Placebo: Matching intravenous infusion
Randomization: 1:1 ratio
Primary Endpoint
Change in PACC (Preclinical Alzheimer Cognitive Composite) at Week 240